Perspective Therapeutics, Inc. (CATX)

Market Cap	282.81M
Revenue (ttm)	1.24M
Net Income (ttm)	-94.95M
Shares Out	74.23M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,806,397
Open	3.950
Previous Close	3.980
Day's Range	3.660 - 4.076
52-Week Range	1.600 - 16.550
Beta	1.18
Analysts	Strong Buy
Price Target	12.90 (+238.58%)
Earnings Date	Aug 13, 2025

About CATX

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-α-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 140
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CATX

Financial Performance

In 2024, Perspective Therapeutics's revenue was $1.45 million, an increase of 1.39% compared to the previous year's $1.43 million. Losses were -$79.28 million, 70.5% more than in 2023.

Analyst Forecast

According to 11 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price target is $12.9, which is an increase of 238.58% from the latest price.

Price Target

$12.9

(238.58% upside)

Analyst Consensus: Strong Buy